# DEA Marijuana Decision Moves Closer – What Schedule III > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/marijuana-schedule-iii-impact-michigan-dea-decision/ > **Published:** 2026-08-26T12:30:59-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:46:46-04:00 > **Clinical Summary:** Explore the marijuana schedule III impact on clinical practice and policy in Michigan as the DEA moves closer to reclassification. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyNeurologyResearchMental HealthDosingIndustrySafety Why This Matters This article matters for clinicians and their patients as it discusses the potential reclassification of marijuana from Schedule I to Schedule III by the DEA. Such a change could significantly impact clinical practice by easing restrictions on marijuana research, potentially leading to more evidence-based treatment options for patients. Additionally, a shift in scheduling may influence taxation policies and investment opportunities within the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/), which could affect patient access and affordability of [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) products. Clinical Summary This article discusses the potential reclassification of marijuana from Schedule I to Schedule III by the DEA, which may significantly impact taxation, research, and investment in cannabis across the United States, particularly in Michigan. For clinicians, this could mean increased access to cannabis for therapeutic use due to enhanced research opportunities and potentially improved product quality standards. Dr. Caplan’s Take β€œAs a seasoned family physician specializing in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), the potential shift towards a Schedule III classification for marijuana in Michigan holds promising implications for both patients and the broader medical community. However, it is crucial to acknowledge that while this decision moves us closer to a more accessible and regulated landscape, we must remain vigilant in ensuring evidence-based practices and rigorous research continue to guide our understanding and application of cannabis as a therapeutic agent.” Clinical Perspective πŸ”¬ In the evolving landscape of cannabis regulation, the potential reclassification of marijuana from Schedule I to Schedule III by the DEA could significantly impact clinical practice in Michigan. This shift may facilitate increased access to cannabis for medical purposes, potentially broadening treatment options for qualifying patients. However, it’s crucial to acknowledge the complexity involved, including the need for robust research to fully understand the therapeutic benefits and risks associated with different cannabis strains and dosages. Healthcare providers should remain vigilant about potential confounders such as drug interactions, dosage adjustments, and patient safety considerations when integrating cannabis into treatment plans. Practically, this development may necessitate updates to prescribing guidelines and continued education for healthcare professionals to ensure optimal patient care in the context of a potentially more accessible cannabis market. πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20DEA%20Marijuana%20Decision%20Moves%20Closer%20%E2%80%94%20What%20Schedule%20III%20Could%20Mean%20For%20Michigan%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74878)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74878)[πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20DEA%20Marijuana%20Decision%20Moves%20Closer%20%E2%80%94%20What%20Schedule%20III%20Could%20Mean%20For%20Michigan%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74878)[πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[πŸ“ Read more on Substack](https://doctorapprovedcannabis.substack.com/)[πŸ”” Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Iowa Proposes Medical Cannabis Access for Out-of-State Patients](https://cedclinic.com/iowa-out-of-state-medical-cannabis-access-2026/) - [Military Says Marijuana Rescheduling Still Does Not Permit Use by Service Members](https://cedclinic.com/2026-cannabis-military-policy-changes/) - [State-Licensed Medical Marijuana Reclassified as Less-Dangerous Drug – YouTube](https://cedclinic.com/federal-medical-marijuana-reclassification-impact/) πŸ“° Source: [https://mitechnews.com/news/dea-marijuana-decision-moves-closer-what-schedule-iii-could-mean-for-michigan/](https://mitechnews.com/news/dea-marijuana-decision-moves-closer-what-schedule-iii-could-mean-for-michigan/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Federal marijuana reclassification could reshape medical research and cannabis industry](https://cedclinic.com/federal-marijuana-reclassification-could-reshape-medical-research-and-cannabis-industry/) Learn how federal marijuana reclassification may transform [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) and the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) landscape. [Read More](https://cedclinic.com/federal-marijuana-reclassification-could-reshape-medical-research-and-cannabis-industry/) [The Realities of Rescheduling Medical Cannabis | Rockefeller Institute of Government](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) Explore the practical effects and challenges of rescheduling [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) from a policy perspective. [Explore Insights](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) [Massachusetts Cannabis Regulators Reveal THC Potency Audit Results](https://cedclinic.com/massachusetts-cannabis-regulators-reveal-thc-potency-audit-results/) Review recent findings on THC potency audits that impact cannabis regulation and clinical standards. [Discover Findings](https://cedclinic.com/massachusetts-cannabis-regulators-reveal-thc-potency-audit-results/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).